A popular diabetes drug just got a major new approval — and it could be a game-changer for millions of Americans at risk for kidney failure.

Humana and Monogram Health, a value-based multispecialty provider of in-home care and benefit management services for patients living with kidney disease, have expanded their partnership to patients ...

Study led by Mount Sinai researcher shows sotagliflozin is the only drug in its class to demonstrate these results ...

GLP-1 medications are renowned for their ability to treat type 2 diabetes and aid weight loss. Now, there's a new benefit to ...

Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...

Mineralys Therapeutics, Inc. (NASDAQ: MLYS) has announced the completion of enrollment in the explore-CKD phase 2 trial for ...

“We’ve devoted all of these dollars to infectious disease and to drug development and very little to chronic disease,” Kennedy said Thursday before the Senate Committee on Health ...

Shares of Infinity Natural Resources jumped almost 11% in their NYSE debut, valuing the oil and natural gas producer at $1.3B. The listing ...

Retired NBA All-star revealed that he had kidney cancer and had to get 40% of his kidney removed after going in for ...

may spur progression to kidney failure in patients with chronic kidney disease (CKD), according to 2 nationwide Asian studies. AKI risk was significantly increased 39.5% for the PPI group.

The FDA approval is based on results from the FLOW phase 3b kidney outcomes trial investigating the effects of once-weekly Ozempic injection on major kidney and cardiovascular outcomes in adults with ...